FDA Updates

Drug Topics' poll finds pharmacists against Mevacor going OTC.

FDA issues warning on supplements marketed for ED, sexual enhancement

Legislation introduced to restrict access to DHEA

FDA's final rule mandates warning for nonoxynol 9 OTC contraceptives

CHPA supports FDA's recommendations on phenylephrine

Natural Products Association responds to MLB's Mitchell Report

CHPA responds to NIDA's cough medicine abuse monitoring survey

FDA advisory panel rejects Merck's bid for OTC Mevacor

Drug Topics poll: R.Ph.s favor BTC class of drugs

The FDA has approved Ixabepilone (Ixempra) as a monotherapy and in combination with capecitabine (Xeloda) for patients with metastic or locally advanced breast cancer.

The new products include branded drugs, new formulations, new indications, and new dosing, along with OTCs and home health and beauty items.

Pharmacists' organizations were out in force at a recent FDA hearing on the possibility of creating a third category of drugs that would be placed "behind-the-counter" and pharmacist-assisted.

Rxs for Xenical down since OTC Alli released

Sens. John Kerry, Diane Feinstein, and Barbara Boxer urge the FDA to test lipstick for lead

ASHP believes Mevacor is not safe to go over the counter but might be appropriate for behind the counter.

Sens. John Kerry, Diane Feinstein, and Barbara Boxer urge the FDA to test lipstick for lead

Study finds consumers approve of behind-the-counter drugs

FDA extends comment period for proposed sunscreen rule

Software manages and tracks every IV dose administered by hospitals

FDA, Bodee LLC issue nationwide recall of Encore Tablets

FDA, Bodee LLC issue nationwide recall of Encore Tablets

New products include brand-name drugs, generics, home-health products, over-the-counter, and health and beauty care.

Peggy Memoli is recognized for her work with Alzheimer's patients. She is one of three recipients of 2007 Eisai award recognizing the role of pharmacists in Alzheimer's care.

This drug combines an antihistamine with a nasal decongestant.

Manufacturers are launching new over-the-counter medicines that are innovative.

Two Food and Drug Administration advisory committees voted 13 to 9 to recommend that cough and cold over-the-counter medications not be used for children who are more than two and less than six years old.

At an FDA public meeting to consider whether a behind-the-counter class of drugs should be set up, the agency heard from both supporters and detractors.

APHA adopts policy against feminine hygiene douching practices